These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9683555)

  • 1. Soluble CD16 in the treatment of murine lupus nephritis.
    Watanabe H; Sherris D; Gilkeson GS
    Clin Immunol Immunopathol; 1998 Jul; 88(1):91-5. PubMed ID: 9683555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
    Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
    Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of major histocompatibility complex (MHC) to upregulation of anti-DNA antibody in transgenic mice.
    Song YW; Tsao BP; Hahn BH
    J Autoimmun; 1993 Feb; 6(1):1-9. PubMed ID: 8457281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice.
    Moser K; Kalies K; Szyska M; Humrich JY; Amann K; Manz RA
    Arthritis Rheum; 2012 Apr; 64(4):1237-46. PubMed ID: 22006377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice.
    Gatto M; Ghirardello A; Luisetto R; Bassi N; Fedrigo M; Valente M; Valentino S; Del Prete D; Punzi L; Doria A
    J Autoimmun; 2016 Nov; 74():208-216. PubMed ID: 27405845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of lupus nephritis development in NZB/NZW mice by selective blockade of CD28.
    Laurent L; Le Fur A; Bloas RL; Néel M; Mary C; Moreau A; Poirier N; Vanhove B; Fakhouri F
    Eur J Immunol; 2017 Aug; 47(8):1368-1376. PubMed ID: 28631301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis.
    Cheng Q; Mumtaz IM; Khodadadi L; Radbruch A; Hoyer BF; Hiepe F
    Ann Rheum Dis; 2013 Dec; 72(12):2011-7. PubMed ID: 24114925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice.
    Yoshida H; Satoh M; Behney KM; Lee CG; Richards HB; Shaheen VM; Yang JQ; Singh RR; Reeves WH
    Arthritis Rheum; 2002 Aug; 46(8):2235-44. PubMed ID: 12209530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
    Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
    Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
    Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
    J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymic microenvironment and NZB mice: the abnormal thymic microenvironment of New Zealand mice correlates with immunopathology.
    Takeoka Y; Taguchi N; Kotzin BL; Bennett S; Vyse TJ; Boyd RL; Naiki M; Konishi J; Ansari AA; Shultz LD; Gershwin ME
    Clin Immunol; 1999 Mar; 90(3):388-98. PubMed ID: 10075868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of renal disease and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus (SLE) by chenodeoxycholic acid.
    Suwannaroj S; Lagoo A; McMurray RW
    Lupus; 2001; 10(8):562-7. PubMed ID: 11530998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
    Daikh DI; Wofsy D
    J Immunol; 2001 Mar; 166(5):2913-6. PubMed ID: 11207238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of renal disease in autoimmune NZB/NZW mice by immunization with bacterial DNA.
    Gilkeson GS; Ruiz P; Pippen AM; Alexander AL; Lefkowith JB; Pisetsky DS
    J Exp Med; 1996 Apr; 183(4):1389-97. PubMed ID: 8666897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.
    Jacob CO; van der Meide PH; McDevitt HO
    J Exp Med; 1987 Sep; 166(3):798-803. PubMed ID: 3114409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of murine lupus with TIGIT-Ig.
    Liu S; Sun L; Wang C; Cui Y; Ling Y; Li T; Lin F; Fu W; Ding M; Zhang S; Lei C; Hu S
    Clin Immunol; 2019 Jun; 203():72-80. PubMed ID: 31005675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C1q regulatory region polymorphism down-regulating murine c1q protein levels with linkage to lupus nephritis.
    Miura-Shimura Y; Nakamura K; Ohtsuji M; Tomita H; Jiang Y; Abe M; Zhang D; Hamano Y; Tsuda H; Hashimoto H; Nishimura H; Taki S; Shirai T; Hirose S
    J Immunol; 2002 Aug; 169(3):1334-9. PubMed ID: 12133956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effect of polyclonal immunoglobulins from malaria-infected BALB/c mice on the lupus-like syndrome of (NZB x NZW)F1 mice.
    Hentati B; Sato MN; Payelle-Brogard B; Avrameas S; Ternynck T
    Eur J Immunol; 1994 Jan; 24(1):8-15. PubMed ID: 8020574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against renal disease in (NZB x NZW)F(1) lupus-prone mice after somatic B cell gene vaccination with anti-DNA immunoglobulin consensus peptide.
    Ferrera F; Hahn BH; Rizzi M; Anderson M; Fitzgerald J; Millo E; Indiveri F; Shi FD; Filaci G; La Cava A
    Arthritis Rheum; 2007 Jun; 56(6):1945-53. PubMed ID: 17530718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed lupus onset in (NZB x NZW)F1 mice expressing a human C-reactive protein transgene.
    Szalai AJ; Weaver CT; McCrory MA; van Ginkel FW; Reiman RM; Kearney JF; Marion TN; Volanakis JE
    Arthritis Rheum; 2003 Jun; 48(6):1602-11. PubMed ID: 12794828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.